Autor: |
Melissa J. Harnois, Richard Barfield, Maria Dennis, Nicole Rodgers, Justin Pollara, Connor S. Spies, Laurie D. Snyder, Cliburn Chan, Annette M. Jackson, Scott M. Palmer, Sallie R. Permar |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
JHLT Open, Vol 5, Iss , Pp 100113- (2024) |
Druh dokumentu: |
article |
ISSN: |
2950-1334 |
DOI: |
10.1016/j.jhlto.2024.100113 |
Popis: |
Background: Cytomegalovirus (CMV) is the most common viral infection among lung transplant recipients and is associated with chronic lung allograft dysfunction. There is a need for better therapeutics as well as biomarkers to enable effective stratification of CMV seropositive patient risk for developing CMV DNAemia to inform prophylaxis duration. Methods: CMV-specific immunoglobulin G (IgG) binding and functional responses were evaluated in a discovery cohort of longitudinal plasma samples from 51 CMV seropositive human lung transplant recipients, collected as part of the clinical trials in organ transplantation (CTOT)-20 and CTOT-22 consortium studies. Pre-transplant plasma from an additional 43 CMV seropositive lung transplant recipients was evaluated as a validation cohort. Results: In the discovery cohort with longitudinal samples, pre-transplant plasma IgG binding to CMV surface glycoproteins glycoprotein H (gH)/glycoprotein L (gL), gH/gL/glycoprotein O (gO), and pentameric complex, as well as neutralization of CMV in epithelial cells, is associated with increased risk of CMV DNAemia post-prophylaxis. However, these results were not confirmed by the validation cohort. Conclusions: While quantification of pre-transplant CMV-specific antibody responses showed association with DNAemia in the discovery cohort, additional clinical variables and/or known risk factors for CMV, such as patient CMV-specific T-cell responses, may need to be considered in combination with humoral immunity to effectively stratify risk of CMV DNAemia. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|